While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Images of plants painted on pottery made up to 8,000 years ago may be the earliest example of humans’ mathematical thought, a study has found.

Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...

Unless you worked for Ford’s plastics, paint and vinyls division in the 1980s, you probably don’t know the name Jim Moylan. But you might well know the idea that made this unknown engineer who ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Ashely Claudino is an Evergreen Staff Writer from Portugal. She has a Translation degree from the University of Lisbon (2020, Faculty of Arts and Humanities). Nowadays, she mostly writes Fortnite and ...

For simplicity, employers might prefer the SIMPLE IRA. For flexibility, a 401(k) plan provides a wider array of choices. Many, or all, of the products featured on this page are from our advertising ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...